AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24915914 — intervention group
Group type: EXPERIMENTAL
Intervention: HHHFNC
Number of subjects: 255
Study 24915914 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 255
Study 23211845 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8844
Study 23211845 — intervention group
Group type: EXPERIMENTAL
Intervention: CT Colonography
Number of subjects: 8844
Study 20553804 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 15Hz tACS with a current density of 0.80A/m(2) for 20 minutes
Number of subjects: 0
Study 20553804 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 0
Study 18285478 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (600 mg BID)
Number of subjects: 37
Study 18285478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (400 mg BID) plus ritonavir (100 or 200 mg BID)
Number of subjects: 37
Study 18285478 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of amprenavir and lopinavir
Number of subjects: 37
Study 18285478 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir and lopinavir concentrations
Number of subjects: 37
Study 15811048 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouth rinse containing 0.09% zinc chloride (Tartar Control Listerine Antiseptic)
Number of subjects: 0
Study 15811048 — intervention group
Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 0
Study 12761806 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily controlled-release formulation of divalproex sodium
Number of subjects: 0
Study 12761806 — intervention group
Group type: COMPARATOR
Intervention: Commercial enteric tablet dosed twice-daily
Number of subjects: 0
Study 10227321 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (household and office-based patient educational materials, clinician education, practice-profiling, academic detailing)
Number of subjects: 2027
Study 10227321 — intervention group
Group type: COMPARATOR
Intervention: Limited intervention (only office-based educational materials)
Number of subjects: 2027
Study 10227321 — intervention group
Group type: COMPARATOR
Intervention: Control sites (usual care)
Number of subjects: 2027
Study 10227321 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 2027
Study 10227321 — intervention group
Group type: COMPARATOR
Intervention: All sites
Number of subjects: 2027
Study 9118303 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg orally twice a day)
Number of subjects: 59
Study 9118303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 1714950 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) alternating with ABVD (doxorubicin, vinblastine, bleomycin, and dacarbazine) followed by low-dose radiotherapy (RT)
Number of subjects: 62
Study 1714950 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD followed by low-dose RT
Number of subjects: 62
Study 6223528 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 113
Study 6223528 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 113
Study 31287897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled version of the intervention
Number of subjects: 286
Study 31287897 — intervention group
Group type: COMPARATOR
Intervention: Free-roam version of the intervention
Number of subjects: 286
Study 31287897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tunneled and free-roam interventions
Number of subjects: 286
Study 28423301 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (90 mg and 180 mg doses at weeks 0, 4, and 16)
Number of subjects: 166
Study 28423301 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (45 or 90 mg doses at weeks 0, 4, and 16)
Number of subjects: 166
Study 28423301 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (18 mg, 90 mg, and 180 mg doses)
Number of subjects: 166
Study 28423301 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (45 or 90 mg doses)
Number of subjects: 166
Study 24214970 — intervention group
Group type: EXPERIMENTAL
Intervention: High EPA supplementation
Number of subjects: 90
Study 24214970 — intervention group
Group type: EXPERIMENTAL
Intervention: High DHA supplementation
Number of subjects: 90
Study 24214970 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid (control)
Number of subjects: 90
Study 24214970 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased erythrocyte EPA + DHA
Number of subjects: 90
Study 24084323 — intervention group
Group type: EXPERIMENTAL
Intervention: Open insertion with omentum folding (OIOF group)
Number of subjects: 67
Study 24084323 — intervention group
Group type: COMPARATOR
Intervention: Regular open insertion (ROI group)
Number of subjects: 67
Study 21114607 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 929
Study 21114607 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 929
Study 21114607 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 4 mg once daily
Number of subjects: 929
Study 21114607 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 929
Study 21114607 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 929
Study 20396719 — intervention group
Group type: EXPERIMENTAL
Intervention: Artrofoon treatment for 2 years
Number of subjects: 0
Study 17126719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 1222
Study 17126719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study 14970135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine-filled ETT cuff with water-soluble gel lubrication (Group G)
Number of subjects: 20
Study 14970135 — intervention group
Group type: COMPARATOR
Intervention: Alkalinized lidocaine-filled ETT cuff with water lubrication (Group W)
Number of subjects: 20
Study 14970135 — intervention group
Group type: COMPARATOR
Intervention: Air-filled cuff with water lubrication (Group C)
Number of subjects: 20
Study 14970135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine-filled cuffs (Group G and W)
Number of subjects: 20
Study 14970135 — intervention group
Group type: COMPARATOR
Intervention: Air-filled cuffs (Group C)
Number of subjects: 20
Study 11335782 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-item version of the Questionnaire for Identifying Children With Chronic Conditions (QuICCC-R)
Number of subjects: 1182
Study 11335782 — intervention group
Group type: COMPARATOR
Intervention: 39-item version of the Questionnaire for Identifying Children With Chronic Conditions (QuICCC)
Number of subjects: 1182
Study 9143860 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1)
Number of subjects: 71
Study 9143860 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2)
Number of subjects: 71
Study 9143860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 8182635 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group physical therapy (3 hours weekly)
Number of subjects: 144
Study 8182635 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised daily individualized exercises at home (9 months)
Number of subjects: 144
Study 2451712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 184
Study 2451712 — intervention group
Group type: COMPARATOR
Intervention: MVVPP
Number of subjects: 184
Study 2451712 — intervention group
Group type: COMPARATOR
Intervention: MOPP-ABVD
Number of subjects: 184
Study 31326956 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoured tobacco
Number of subjects: 144
Study 31326956 — intervention group
Group type: COMPARATOR
Intervention: Unflavoured tobacco
Number of subjects: 144
Study 30961592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal breakfast
Number of subjects: 24
Study 30961592 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg and ham breakfast
Number of subjects: 24
Study 27761661 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-axis out-of-plane (SA-OOP) technique
Number of subjects: 150
Study 27761661 — intervention group
Group type: COMPARATOR
Intervention: Long-axis in-plane (LA-IP) technique
Number of subjects: 150
Study 25872667 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (acupoints: triple energizer 5, 'Wai‐guan' and large intestine 11, 'Qu‐chi')
Number of subjects: 12
Study 25872667 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 12
Study 23104965 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Plus Children's Programme (PPCP)
Number of subjects: 29
Study 23104965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 21660907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal small-caliber esophagogastroduodenoscopy (TNSC-EGD)
Number of subjects: 100
Study 21660907 — intervention group
Group type: COMPARATOR
Intervention: Peroral conventional esophagogastroduodenoscopy (POC-EGD)
Number of subjects: 100
Study 17615567 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib for 21 days
Number of subjects: 11
Study 17615567 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 11
Study 16848777 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ACA velocity (> or =170 cm/s)
Number of subjects: 1975
Study 16848777 — intervention group
Group type: COMPARATOR
Intervention: Normal ACA velocity
Number of subjects: 1975
Study 16848777 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ACA velocity in subjects with normal ICA/MCA velocity
Number of subjects: 1975
Study 16848777 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ACA velocity in high-risk subjects (abnormal ICA/MCA findings)
Number of subjects: 1975
Study 15354698 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-novelty manipulation (high self-focus condition)
Number of subjects: 0
Study 15354698 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (neutral topics or no writing)
Number of subjects: 0
Study 11422727 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fluvoxamine
Number of subjects: 14
Study 11422727 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 14
Study 11422727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment
Number of subjects: 14
Study 11422727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine and paroxetine treatment
Number of subjects: 14
Study 11422727 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute discontinuation
Number of subjects: 14
Study 9827848 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 [7‐36 amide]
Number of subjects: 8
Study 9827848 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 [7‐37]
Number of subjects: 8
Study 8129449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral flucloxacillin 250 mg/day (group P, n = 18)
Number of subjects: 38
Study 8129449 — intervention group
Group type: COMPARATOR
Intervention: Episodic antimicrobials as clinically indicated (group E, n = 20)
Number of subjects: 38
Study 2808961 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care information intervention (one page of general information and a booklet)
Number of subjects: 391
Study 2808961 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care information intervention
Number of subjects: 391
Study 2808961 — intervention group
Group type: COMPARATOR
Intervention: Control group (survey instrument only)
Number of subjects: 391
Study 15811704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 14
Study 15811704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31037288 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 422
Study 31037288 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab and pertuzumab
Number of subjects: 422
Study 31037288 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib alone
Number of subjects: 422
Study 30883336 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐337‐3p mimic
Number of subjects: 5
Study 30883336 — intervention group
Group type: COMPARATOR
Intervention: Rap1A
Number of subjects: 5
Study 30883336 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐337‐3p mimic + Rap1A
Number of subjects: 5
Study 30883336 — intervention group
Group type: COMPARATOR
Intervention: Mock
Number of subjects: 5
Study 28158243 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 42
Study 28158243 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 42
Study 28158243 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 42
Study 25156424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried California Mission figs (120 g/d)
Number of subjects: 88
Study 25156424 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 88
Study 23681294 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-repeat carriers of the DAT1 gene
Number of subjects: 100
Study 23681294 — intervention group
Group type: COMPARATOR
Intervention: 10/10 homozygotes of the DAT1 gene
Number of subjects: 100
Study 23681294 — intervention group
Group type: COMPARATOR
Intervention: DBH5'-ins/del polymorphism
Number of subjects: 100
Study 21442809 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongzhu (TE 3) and Waiguan (TE 5)
Number of subjects: 60
Study 21442809 — intervention group
Group type: COMPARATOR
Intervention: Routine medicine, physical therapy, occupational therapy, and other rehabilitation trainings
Number of subjects: 60
Study 19845037 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (arm A; n = 59)
Number of subjects: 123
Study 19845037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm B; n = 64)
Number of subjects: 123
Study 19845037 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (arm A)
Number of subjects: 123
Study 19845037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm B)
Number of subjects: 123
Study 16762759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophic cardiomyopathy (HC) patients
Number of subjects: 26
Study 16762759 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study 15205238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasis
Number of subjects: 398
Study 15205238 — intervention group
Group type: COMPARATOR
Intervention: Undilated single field photography
Number of subjects: 398
Study 15205238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated single field photography
Number of subjects: 398
Study 15205238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated three field photography
Number of subjects: 398
Study 11742271 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 0.31 mg
Number of subjects: 338
Study 11742271 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 0.63 mg
Number of subjects: 338
Study 11742271 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC 1.25 mg
Number of subjects: 338
Study 11742271 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC 2.5 mg
Number of subjects: 338
Study 11742271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 11742271 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 338
Study 9241391 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized AIDS education
Number of subjects: 300
Study 9241391 — intervention group
Group type: COMPARATOR
Intervention: Traditional AIDS education
Number of subjects: 300
Study 8359579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicilate (450 mg i.v.)
Number of subjects: 8
Study 8359579 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl)
Number of subjects: 8
Study 31776029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 687
Study 31776029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 29169057 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health workers (LHWs) providing instrumental, informational, emotional, and appraisal support.
Number of subjects: 0
Study 29169057 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic social support (SSS) provided by LHWs.
Number of subjects: 0
Study 28239036 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fondaparinux
Number of subjects: 50
Study 28239036 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral edoxaban
Number of subjects: 50
Study 28239036 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 26137702 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoaiping injection (60 mL, i.v., qd)
Number of subjects: 66
Study 23032922 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC D-Blade (DB)
Number of subjects: 96
Study 23032922 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 96
Study 23032922 — intervention group
Group type: COMPARATOR
Intervention: Direct Macintosh laryngoscopy (DL)
Number of subjects: 96
Study 21114342 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 403
Study 21114342 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 403
Study 18242128 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2548
Study 18242128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2548
Study 16357551 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy supplemented with partial weight‐bearing gait training twice weekly
Number of subjects: 38
Study 16357551 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 38
Study 12708605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevert, ARL)
Number of subjects: 30
Study 12708605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 50 mg
Number of subjects: 30
Study 12708605 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine dimesylate 12 mg
Number of subjects: 30
Study 12708605 — intervention group
Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 30
Study 10905448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cued condition
Number of subjects: 60
Study 10905448 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cued condition
Number of subjects: 60
Study 10905448 — intervention group
Group type: EXPERIMENTAL
Intervention: One-pair digits
Number of subjects: 60
Study 10905448 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-pair digits
Number of subjects: 60
Study 8642030 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution after closure of the wound (Group 2)
Number of subjects: 82
Study 8642030 — intervention group
Group type: COMPARATOR
Intervention: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution before the incision (Group 1)
Number of subjects: 82
Study 8642030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 mL of plain saline solution for both injections, Group 3)
Number of subjects: 82
Study 1731547 — intervention group
Group type: COMPARATOR
Intervention: Propofol for induction and isoflurane-nitrous oxide for maintenance (control)
Number of subjects: 75
Study 1731547 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol for induction and sevoflurane-nitrous oxide for maintenance
Number of subjects: 75
Study 1731547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide for induction and maintenance
Number of subjects: 75
Study 1731547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 75
Study 1731547 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-nitrous oxide
Number of subjects: 75
Study 6487945 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal heart rates assessed during workloads of 600 kpm
Number of subjects: 24
Study 6487945 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal heart rates assessed during workloads of 750 kpm
Number of subjects: 24
Study 6487945 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal heart rates assessed during workloads of 900 kpm
Number of subjects: 24
Study 6487945 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial testing occasion
Number of subjects: 24
Study 6487945 — intervention group
Group type: EXPERIMENTAL
Intervention: Second testing condition
Number of subjects: 24
Study 29103656 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 200
Study 29103656 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 200
Study 27183253 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT
Number of subjects: 141
Study 27183253 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 141
Study 27183253 — intervention group
Group type: COMPARATOR
Intervention: ADAPT and HEART Pathway
Number of subjects: 141
Study 24343853 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning educational program
Number of subjects: 10
Study 24343853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 22771049 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with epinephrine 1:100 000
Number of subjects: 54
Study 22771049 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered 2% lidocaine with epinephrine 1:100 000
Number of subjects: 54
Study 20614235 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG Biofeedback (Neurofeedback‐NFB) treatment, 20 sessions over 4 weeks
Number of subjects: 36
Study 20614235 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram treatment, 10 mg per day for 8 weeks
Number of subjects: 36
Study 20614235 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG Biofeedback (Neurofeedback‐NFB) treatment
Number of subjects: 36
Study 20614235 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram treatment
Number of subjects: 36